Skip to main content

Table 2 Patients’ basic demographic variables and treatments

From: Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series

  Survivors Non-survivors
Patient ID 2 3 4 8 10 11 1* 5 6 7 9
Hospital 1 1 2 1 2 2 1 2 2 1 2
Cell type** UC-MSC UC-MSC UC-MSC PL-MSC PL-MSC PL-MSC UC-MSC UC-MSC UC-MSC PL-MSC PL-MSC
Age (years)*** 60–65 55–60 65–70 60–65 40–45 45–50 65–70 50–55 55–60 35–40 60–65
Sex (1/2)*** 2 2 1 1 1 1 2 1 1 1 1
Weight (kg) 80 69 60 95 85 103 80 80 87 85 94
Underlying disease HTN, DM CLL CMP, DM HTN HTN, DM DM
Treatment protocol HCQ, Kaletra HCQ, Kaletra HCQ, Kaletra, Azithromycin, IVIG, Ribavarin HCQ, Kaletra Meropenem, Vancomycin, IVIG,
Favipiravir
Kaletra, Meropenem, Vancomycin, Tamiflu, IVIG, Favipiravir HCQ, Kaletra HCQ, Kaletra, Azithromycin, IVIG, + ECMO Kaletra, Ribavirin, Vancomycin, Imiper, IVIG HCQ, Kaletra Kaletra, Meropenem, Colistin, IVIG
qRT-PCR + + + + + + + + + +
  1. HCQ hydroxychloroquine, HTN hypertension, DM diabetes mellitus, IVIG intravenous immunoglobulin, ECMO extracorporeal membrane oxygenation, qRT-PCR quantitative reverse transcription-polymerase chain reaction, CMP cardiomyopathy, CLL chronic lymphocytic leukemia, UC-MSC umbilical cord mesenchymal stem cells, PL-MSC placental MSC
  2. *qRT-PCR in this patient was initially negative but history, clinical presentation, and radiography of the patient were indicative of COVID-19 infection
  3. **UC-MSCs were freeze/thawed prior to infusion; however, PL-MSCs were freshly administered
  4. ***To avoid the patients/participants identity being revealed, age presented as a range and gender as (1/2)